ADA2

adenosine deaminase 2, the group of Adenosine deaminase family

Basic information

Region (hg38): 22:17178790-17258235

Previous symbols: [ "IDGFL", "CECR1" ]

Links

ENSG00000093072NCBI:51816OMIM:607575HGNC:1839Uniprot:Q9NZK5AlphaFoldGenCCjaxSfariGnomADPubmedClinVar

Phenotypes

GenCC

Source: genCC

  • vasculitis due to ADA2 deficiency (Strong), mode of inheritance: AR
  • Sneddon syndrome (Moderate), mode of inheritance: AR
  • polyarteritis nodosa (Moderate), mode of inheritance: AR
  • Diamond-Blackfan anemia (Supportive), mode of inheritance: AD
  • Sneddon syndrome (Supportive), mode of inheritance: AD
  • vasculitis due to ADA2 deficiency (Supportive), mode of inheritance: AR
  • vasculitis due to ADA2 deficiency (Strong), mode of inheritance: AR
  • deficiency of adenosine deaminase 2 (Definitive), mode of inheritance: AR

Clinical Genomic Database

Source: CGD

ConditionInheritanceIntervention CategoriesIntervention/Rationale Manifestation CategoriesReferences
Vasculitis, autoinflammation, immunodeficiency, and hematologic defects syndrome; Sneddon syndromeARAllergy/Immunology/InfectiousAmong other manifestations, individuals have been described as presenting with hypogammaglobulinemia, as well as recurrent bacterial and viral infections, and immunosuppressive treatment has been described as beneficial, though other manifestations have been described as recalcitrant to these types of therapies; Medical management (eg, with TNF inhibitor) has been described as beneficial.Allergy/Immunology/Infectious; Cardiovascular; Dermatologic12804991; 24552284; 24552285; 25075844; 25075847

ClinVar

This is a list of variants' phenotypes submitted to ClinVar and linked to the ADA2 gene.

  • Vasculitis due to ADA2 deficiency (34 variants)
  • not provided (8 variants)
  • Vasculitis due to ADA2 deficiency;Sneddon syndrome (3 variants)
  • ADA2-related disorder (3 variants)
  • Sneddon syndrome (3 variants)
  • Sneddon syndrome;Vasculitis due to ADA2 deficiency (2 variants)
  • Autoinflammatory syndrome (1 variants)
  • See cases (1 variants)

Variants pathogenicity by type

Statistics on ClinVar variants can assist in determining whether a specific variant type in the ADA2 gene is commonly pathogenic or not.

In the table, we include only reliable ClinVar variants with their consequences to MANE Select, Mane Plus Clinical transcripts, or transcripts with TSL equals 1. Click the count to view the source variants.

Warning: slight differences between displayed counts and the number of variants in ClinVar may occur, primarily due to (1) the application of a different transcript and/or consequence by our variant effect predictor or (2) differences in clinical significance: we classify Benign/Likely benign variants as Likely benign and Pathogenic/Likely pathogenic variants as Likely pathogenic.

Variant type Pathogenic Likely pathogenic VUS Likely benign Benign Sum
synonymous
3
clinvar
77
clinvar
3
clinvar
83
missense
9
clinvar
13
clinvar
203
clinvar
4
clinvar
1
clinvar
230
nonsense
7
clinvar
2
clinvar
9
start loss
2
clinvar
1
clinvar
3
frameshift
12
clinvar
4
clinvar
16
inframe indel
1
clinvar
1
splice donor/acceptor (+/-2bp)
4
clinvar
6
clinvar
10
splice region
1
10
19
1
31
non coding
1
clinvar
1
clinvar
49
clinvar
34
clinvar
85
Total 36 25 208 130 38

Highest pathogenic variant AF is 0.000171

Variants in ADA2

This is a list of pathogenic ClinVar variants found in the ADA2 region.

You can filter this list by clicking the number of variants in the Variants pathogenicity by type table.

Position Type Phenotype Significance ClinVar
22-17181488-T-G Vasculitis due to ADA2 deficiency • Sneddon syndrome;Vasculitis due to ADA2 deficiency Uncertain significance (May 27, 2022)474907
22-17181497-C-T Vasculitis due to ADA2 deficiency Uncertain significance (Aug 17, 2022)1409286
22-17181506-T-C Vasculitis due to ADA2 deficiency Uncertain significance (Jul 30, 2022)1905176
22-17181518-A-G Uncertain significance (Jun 16, 2016)421492
22-17181522-C-T Vasculitis due to ADA2 deficiency Likely benign (Jan 01, 2023)1117194
22-17181545-T-C Vasculitis due to ADA2 deficiency • ADA2-related disorder Uncertain significance (May 09, 2023)854562
22-17181546-A-ATT Vasculitis due to ADA2 deficiency Likely pathogenic (Jan 18, 2024)1901465
22-17181552-C-G Vasculitis due to ADA2 deficiency • not specified • Autoinflammatory syndrome Conflicting classifications of pathogenicity (Dec 28, 2023)569098
22-17181554-C-G Vasculitis due to ADA2 deficiency • Autoinflammatory syndrome • Vasculitis due to ADA2 deficiency;Sneddon syndrome Uncertain significance (Sep 01, 2022)541736
22-17181554-C-T Autoinflammatory syndrome Uncertain significance (Jul 23, 2021)1694257
22-17181564-C-T Vasculitis due to ADA2 deficiency Likely benign (Apr 26, 2022)2181010
22-17181567-G-C Vasculitis due to ADA2 deficiency Likely benign (Sep 29, 2022)2030834
22-17181567-GGTACT-G Vasculitis due to ADA2 deficiency Pathogenic (May 08, 2023)800755
22-17181572-T-G Vasculitis due to ADA2 deficiency Likely pathogenic (Mar 25, 2024)3064951
22-17181574-T-C Vasculitis due to ADA2 deficiency Uncertain significance (Oct 24, 2022)1489106
22-17181576-C-A Vasculitis due to ADA2 deficiency Uncertain significance (Jan 15, 2024)973613
22-17181582-G-C Vasculitis due to ADA2 deficiency Likely benign (Dec 11, 2023)2802119
22-17181583-GA-G Vasculitis due to ADA2 deficiency Likely benign (Aug 07, 2023)1092493
22-17181586-G-T Vasculitis due to ADA2 deficiency Likely benign (Oct 13, 2021)1549597
22-17181589-G-A Vasculitis due to ADA2 deficiency Likely benign (Oct 28, 2021)1654249
22-17181592-G-A Vasculitis due to ADA2 deficiency Likely benign (Mar 10, 2022)1356001
22-17181594-G-A Vasculitis due to ADA2 deficiency Likely benign (Sep 02, 2022)2028531
22-17181701-C-G not specified Benign (Nov 12, 2023)1285778
22-17181789-C-T not specified Benign (Nov 12, 2023)1266748
22-17181800-G-C Vasculitis due to ADA2 deficiency Likely benign (Dec 04, 2022)1603384

GnomAD

Source: gnomAD

GeneTypeBio TypeTranscript Coding Exons Length
ADA2protein_codingprotein_codingENST00000399839 942686
pLI Probability
LOF Intolerant
pRec Probability
LOF Recessive
Individuals with
no LOFs
Individuals with
Homozygous LOFs
Individuals with
Heterozygous LOFs
Defined p
8.14e-80.7361256670801257470.000318
Z-Score Observed Expected Observed/Expected Mutation Rate Total Possible in Transcript
Missense0.3572802970.9420.00001593403
Missense in Polyphen8790.4780.961561101
Synonymous0.3671081130.9560.00000657959
Loss of Function1.321420.50.6840.00000104239

LoF frequencies by population

EthnicitySum of pLOFs p
African & African-American0.0007930.000793
Ashkenazi Jewish0.000.00
East Asian0.0001090.000109
Finnish0.00004640.0000462
European (Non-Finnish)0.0003880.000387
Middle Eastern0.0001090.000109
South Asian0.0002290.000229
Other0.0003260.000326

dbNSFP

Source: dbNSFP

Function
FUNCTION: Adenosine deaminase that may contribute to the degradation of extracellular adenosine, a signaling molecule that controls a variety of cellular responses. Requires elevated adenosine levels for optimal enzyme activity. Binds to cell surfaces via proteoglycans and may play a role in the regulation of cell proliferation and differentiation, independently of its enzyme activity. {ECO:0000269|PubMed:20147294, ECO:0000269|PubMed:20453107}.;
Disease
DISEASE: Polyarteritis nodosa (PAN) [MIM:615688]: A systemic necrotizing vasculitis that affects medium and small arteries. The ensuing tissue ischemia can affect any organ, including the skin, musculoskeletal system, kidneys, gastrointestinal tract, and the cardiovascular and nervous systems. Organ involvement and disease severity are highly variable. Clinical features include recurrent ischemic stroke affecting the small vessels of the brain and resulting in neurologic dysfunction, recurrent fever, myalgias, livedoid rash, gastrointestinal pain and hepatosplenomegaly. {ECO:0000269|PubMed:24552284, ECO:0000269|PubMed:24552285}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Sneddon syndrome (SNDDS) [MIM:182410]: A systemic non- inflammatory thrombotic vasculopathy characterized by the association of livedo racemosa, and in some cases livedo reticularis, with cerebrovascular disease. Livedo racemosa is a persistent net-like violaceous-cyanotic, mottled discoloration of the skin affecting the legs, the arms, the buttocks and the trunk; livedo reticularis is limited to the extremities and is visible only in the cold. Cerebrovascular features include recurrent transient ischemic attacks, infarcts, and rarely spinal strokes or intracranial or subarachnoid hemorrhages. Headache and vertigo may precede the onset of livedo racemosa and cerebrovascular manifestations by several years. Rare neurologic symptoms include seizures, chorea, or myelopathies. {ECO:0000269|PubMed:25075847}. Note=The disease is caused by mutations affecting the gene represented in this entry.;
Pathway
Purine metabolism - Homo sapiens (human);Neutrophil degranulation;Surfactant metabolism;Metabolism of proteins;Innate Immune System;Immune System (Consensus)

Recessive Scores

pRec
0.0931

Intolerance Scores

loftool
rvis_EVS
-0.35
rvis_percentile_EVS
29.43

Haploinsufficiency Scores

pHI
0.308
hipred
N
hipred_score
0.187
ghis
0.505

Essentials

essential_gene_CRISPR
essential_gene_CRISPR2
essential_gene_gene_trap
N
gene_indispensability_pred
gene_indispensability_score

Zebrafish Information Network

Gene name
ada2b
Affected structure
neutrophil
Phenotype tag
abnormal
Phenotype quality
decreased amount

Gene ontology

Biological process
adenosine catabolic process;multicellular organism development;regulation of signaling receptor activity;neutrophil degranulation;cellular protein metabolic process;inosine biosynthetic process
Cellular component
extracellular region;extracellular space;azurophil granule lumen
Molecular function
adenosine deaminase activity;growth factor activity;heparin binding;zinc ion binding;adenosine receptor binding;protein homodimerization activity;proteoglycan binding